344850-M
Fumonisin B1, Fusarium moniliforme
A cell-permeable mycotoxin that inhibits sphingolipid biosynthesis in rat kidney and in liver microsomes by inhibition of sphingosine N-acyltransferase (ceramide synthase; IC50 = 100 nM).
别名:
Fumonisin B1, Fusarium moniliforme, FB1
InChI
1S/C34H59NO15/c1-5-6-9-20(3)32(50-31(44)17-23(34(47)48)15-29(41)42)27(49-30(43)16-22(33(45)46)14-28(39)40)13-19(2)12-24(36)10-7-8-11-25(37)18-26(38)21(4)35/h19-27,32,36-38H,5-18,35H2,1-4H3,(H,39,40)(H,41,42)(H,45,46)(H,47,48)/t19-,20+,21+,22+,23+,24+,25-,26+,27-,32-/m1/s1
InChI key
UVBUBMSSQKOIBE-ZWKVXHQASA-N
assay
≥95% (TLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white to beige
solubility
methanol: 5 mg/mL
Quality Level
General description
A cell-permeable mycotoxin that inhibits sphingolipid biosynthesis in rat kidney and in liver microsomes by inhibition of sphingosine N-acyltransferase (ceramide synthase; IC50 = 100 nM). Preferentially inhibits sphingomyelin biosynthesis in neuronal cells. Exhibits carcinogenic properties.
Fumonisin B1 is a neurotoxin and a phytotoxin. A cell-permeable mycotoxin that inhibits sphingolipid biosynthesis in rat kidney and in liver microsomes by inhibition of sphingosine N-acyltransferase (ceramide synthase) (IC50 = 100 nM). Cellular effects also appear to be induced by micromolar levels of FB1. Because it inhibits ceramide synthase activity, it elevates cellular levels of sphingoid bases, including sphinganine, resulting in overall inhibition of sphingolipid biosynthesis. Preferentially inhibits sphingomyelin biosynthesis in neuronal cells. Has carcinogenic properties.
Biochem/physiol Actions
Primary Target
ceramide synthase
ceramide synthase
Target IC50: 100 nM against sphingosine N-acyltransferase (ceramide synthase)
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Other Notes
Wu, W.I., et al. 1995. J. Biol. Chem.270, 13171.
Riley, R.T., et al. 1994. J. Nutr. 124, 594.
Wolf, G. 1994. Nutr. Rev. 52, 246.
Merrill, A.H. Jr., et al. 1993. Adv. Lipid Res.26, 215.
Merrill, Jr., A.H., et al. 1993. J. Biol. Chem.268, 27299.
Voss, K.A., et al. 1993. Nat. Toxins1, 222.
Wang, E., et al. 1991. J. Biol. Chem.266, 14486.
Harrison, L.R., et al. 1990. J. Vet. Diag. Invest. 2, 217.
Riley, R.T., et al. 1994. J. Nutr. 124, 594.
Wolf, G. 1994. Nutr. Rev. 52, 246.
Merrill, A.H. Jr., et al. 1993. Adv. Lipid Res.26, 215.
Merrill, Jr., A.H., et al. 1993. J. Biol. Chem.268, 27299.
Voss, K.A., et al. 1993. Nat. Toxins1, 222.
Wang, E., et al. 1991. J. Biol. Chem.266, 14486.
Harrison, L.R., et al. 1990. J. Vet. Diag. Invest. 2, 217.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Carcinogenic / Teratogenic (D)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Carc. 2 - Repr. 2 - STOT RE 2
target_organs
Kidney,Liver
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品-Merck
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持